Limits...
A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC.

Michael M, Wirth A, Ball DL, MacManus M, Rischin D, Mileshkin L, Solomon B, McKendrick J, Milner AD - Br. J. Cancer (2005)

Bottom Line: The overall radiological response rate was 65% (n=23: complete response 4% and partial response 61%) and infield FDG-PET responses were seen in 89% (n=18).There was an improvement or stabilisation of symptoms and quality of life.This regimen was tolerable and produced meaningful responses for patients for whom locoregional control is required, but who are unsuitable for radical CRT.

View Article: PubMed Central - PubMed

Affiliation: The Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Victoria 8006, Australia. michael.michael@petermac.org

ABSTRACT
The role of concurrent chemoradiotherapy (CRT) in patients with non-small-cell lung cancer (NSCLC) unsuitable for radical therapy but who require locoregional treatment has not been defined. The aims of this phase I trial were thus to develop a novel regimen of weekly chemotherapy concurrent with high-dose palliative RT (40 Gy/20 fractions) and assess its tolerability, objective and symptomatic response rates. Eligible patients had stage I-IIIB NSCLC unsuitable for radical RT or limited stage IV disease, ECOG PS

Show MeSH

Related in: MedlinePlus

(A) Progression free-survival for all patients. (The hatched line represents the 95% CI.) (B) The OS curve for all 24 patients. (The hatched line represents the 95% CI.)
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2361626&req=5

fig2: (A) Progression free-survival for all patients. (The hatched line represents the 95% CI.) (B) The OS curve for all 24 patients. (The hatched line represents the 95% CI.)

Mentions: Patients were followed up from commencing protocol treatment to a close-out date of 29 September 2003. One patient was lost to follow-up. The median potential follow-up time was 21.6 months (range 12.4–38.9 months), with all patients having progressed or died at the close-out date. The Kaplan–Meier PFS and OS survival curves are shown in Figure 2A and B. The actuarial PFS was 6.1 months (95% CI 4.5–7.9 months), with the estimated PFS at 6 and 12 months being 54% (95% CI 35–73%) and 8% (95% CI 2–28%), respectively.


A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC.

Michael M, Wirth A, Ball DL, MacManus M, Rischin D, Mileshkin L, Solomon B, McKendrick J, Milner AD - Br. J. Cancer (2005)

(A) Progression free-survival for all patients. (The hatched line represents the 95% CI.) (B) The OS curve for all 24 patients. (The hatched line represents the 95% CI.)
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2361626&req=5

fig2: (A) Progression free-survival for all patients. (The hatched line represents the 95% CI.) (B) The OS curve for all 24 patients. (The hatched line represents the 95% CI.)
Mentions: Patients were followed up from commencing protocol treatment to a close-out date of 29 September 2003. One patient was lost to follow-up. The median potential follow-up time was 21.6 months (range 12.4–38.9 months), with all patients having progressed or died at the close-out date. The Kaplan–Meier PFS and OS survival curves are shown in Figure 2A and B. The actuarial PFS was 6.1 months (95% CI 4.5–7.9 months), with the estimated PFS at 6 and 12 months being 54% (95% CI 35–73%) and 8% (95% CI 2–28%), respectively.

Bottom Line: The overall radiological response rate was 65% (n=23: complete response 4% and partial response 61%) and infield FDG-PET responses were seen in 89% (n=18).There was an improvement or stabilisation of symptoms and quality of life.This regimen was tolerable and produced meaningful responses for patients for whom locoregional control is required, but who are unsuitable for radical CRT.

View Article: PubMed Central - PubMed

Affiliation: The Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Victoria 8006, Australia. michael.michael@petermac.org

ABSTRACT
The role of concurrent chemoradiotherapy (CRT) in patients with non-small-cell lung cancer (NSCLC) unsuitable for radical therapy but who require locoregional treatment has not been defined. The aims of this phase I trial were thus to develop a novel regimen of weekly chemotherapy concurrent with high-dose palliative RT (40 Gy/20 fractions) and assess its tolerability, objective and symptomatic response rates. Eligible patients had stage I-IIIB NSCLC unsuitable for radical RT or limited stage IV disease, ECOG PS

Show MeSH
Related in: MedlinePlus